by Sveinung W. Sorbye, Thomas K. Kilvaer, Andrej Valkov, Tom Donnem, Eivind Smeland, Khalid Al-Shibli, Roy M. Bremnes, Lill-Tove Busund
The purpose of this study is to clarify the prognostic significance of expression of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas (STS). Optimised treatment of STS requires better identification of high risk patients who will benefit from adjuvant therapy. The prognostic significance of Jab1, p16, p21, p62, Ki67 and Skp2 in STS has not been sufficiently investigated. Experimental Design
Tissue microarrays from 193 STS patients were constructed from duplicate cores of viable and representative neoplastic tumor areas. Immunohistochemistry was used to evaluate the expression of Jab1, p16, p21, p62, Ki67 and Skp2. Results
In univariate analyses, high tumor expression of Ki67 (P?=?0.007) and Skp2 (P?=?0.050) correlated with shorter disease-specific survival (DSS). In subgroup analysis, a correlation between Skp2 and DSS was seen in patients with malignancy grade 1 or 2 (P?=?0.027), tumor size >5 cm (P?=?0.018), no radiotherapy given (P?=?0.029) and no chemotherapy given (P?=?0.017). No such relationship was apparent for Jab1, p16, p21 and p62; but p62 showed a positive correlation to malignancy grade (P?=?0.019). Ki67 was strongly positively correlated to malignancy grade (P?=?0.001). In multivariate analyses, Skp2 was an independent negative prognostic factor for DSS in women (P?=?0.009) and in patients without administered chemotherapy or radiotherapy (P?=?0.026). Conclusions
Increased expression of Skp2 in patients with soft tissue sarcomas is an independent negative prognostic factor for disease-specific survival in women and in patients not administered chemotherapy or radiotherapy. Besides, further studies are warranted to explore if adjuvant chemotherapy or radiotherapy improve the poor prognosis of STS with high Skp2 expression.